Tesamorelin Peptide Research
Tesamorelin is one of the strongest clinically supported GH-axis agents in this database.
ghrh analog
Approved Drug Level
research maturity
Overview
Tesamorelin is one of the strongest clinically supported GH-axis agents in this database. Unlike many secretagogue-style peptides, it has a formal therapeutic identity and meaningful human data, especially in visceral-adiposity settings.
Comparisons
Related stacks
GH Optimization Stack
Advanced Metabolic Stack
Mechanism
As a GHRH analog, tesamorelin stimulates endogenous GH release and increases IGF-1 exposure. Its most established clinical niche is reduction of visceral adiposity in HIV-associated lipodystrophy.
Clinical interest
Clinical interest centers on visceral fat, GH-axis support, and endocrine-directed body-composition management. It is best discussed as a clinically grounded peptide rather than a speculative anti-aging product.
Research summary
The evidence includes major randomized trials, longer-term body-composition work, a recent meta-analysis, and comparative reviews of GHRH analogs. Among non-incretin fat-related peptides, its human evidence is unusually strong.
Safety considerations
Even with stronger evidence, it still requires proper GH/IGF-1-axis monitoring and appropriate patient selection. It should not be overgeneralized to every body-composition use case outside its established evidence base.
Key information
Research stage
Approved Drug Level
Evidence rating
High
Search intent
informational
Last review
Mar 13, 2026
Featured studies
(
7
)
Frequently asked questions
What is tesamorelin?
Tesamorelin is a GHRH analog that stimulates endogenous growth-hormone release and has established clinical use in reducing visceral adiposity in HIV-associated lipodystrophy.
How does tesamorelin compare with sermorelin?
Both are GHRH analogs, but tesamorelin has a stronger modern human evidence base, especially in visceral-fat outcomes.